Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Transaction expected to close in the second quarter of 2020 BOSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its fourth quarter and full year 2019 financial results. In December 2019, Zafgen and Chondrial Therapeutics, Inc., announced that the two companies...
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia Companies to host conference call today at 8:30 a.m. ET BOSTON and BALA CYNWYD, Pa., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) and Chondrial Therapeutics, Inc., today announced they have entered into a definitive merger agreement under which Chondrial will become ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.